Approaches to Develop Alternative Testing Strategies to Inform Human Health Risk Assessment of Nanomaterials.
The development of alternative testing strategies (ATS) for hazard assessment of new and emerging materials is high on the agenda of scientists, funders, and regulators. The relatively large number of nanomaterials on the market and under development means that an increasing emphasis will be placed on the use of reliable, predictive ATS when assessing their safety. We have provided recommendations as to how ATS development for assessment of nanomaterial hazard may be accelerated. Predefined search terms were used to identify the quantity and distribution of peer-reviewed publications for nanomaterial hazard assessment following inhalation, ingestion, or dermal absorption. A summary of knowledge gaps relating to nanomaterial hazard is provided to identify future research priorities and areas in which a rich data set might exist to allow ATS identification. Consultation with stakeholders (e.g., academia, industry, regulators) was critical to ensure that current expert opinion was reflected. The gap analysis revealed an abundance of studies that assessed the local and systemic impacts of inhaled particles, and so ATS are available for immediate use. Development of ATS for assessment of the dermal toxicity of chemicals is already relatively advanced, and these models should be applied to nanomaterials as relatively few studies have assessed the dermal toxicity of nanomaterials to date. Limited studies have investigated the local and systemic impacts of ingested nanomaterials. If the recommendations for research prioritization proposed are adopted, it is envisioned that a comprehensive battery of ATS can be developed to support the risk assessment process for nanomaterials. Some alternative models are available for immediate implementation, while others require more developmental work to become widely adopted. Case studies are included that can be used to inform the selection of alternative models and end points when assessing the pathogenicity of fibers and mode of action of nanomaterial toxicity.
School of Life Sciences, Nano Safety Research Group, Heriot-Watt University, Edinburgh, UK.
Vicki
V
Stone
School of Life Sciences, Nano Safety Research Group, Heriot-Watt University, Edinburgh, UK.
Helinor J
HJ
Johnston
School of Life Sciences, Nano Safety Research Group, Heriot-Watt University, Edinburgh, UK.|Centre for Genomic & Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Dominique
D
Balharry
Department of Energy and Mineral Engineering, The Pennsylvania State University, University Park, PA, USA.
Jeremy M
JM
Gernand
Toxicology and Biochemistry Section NIOH, Johannesburg, South Africa.|Haematology and Molecular Medicine Department School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Mary
M
Gulumian
D006801:Humans; D049329:Nanostructures / Q000633:toxicity*; D036103:Nanotechnology / Q000331:legislation & jurisprudence*; D018570:Risk Assessment; D012449:Safety
3Rs; Alternative testing strategy; gap analysis; hazard, nanomaterials; risk